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Abstract:
Background: Tumor necrosis factor (TNF)-α and -β are cytokines with a wide range of inflammatory, apoptotic and immunomodula-
tory activities. TNF-α promoter −308 G , A polymorphism has been reported to be associated with rheumatoid arthritis (RA) with 
inconsistent results.
Objective: The aim of this study is to elucidate a possible association of TNF-α (G−308Α) and TNF-β (A+252G) polymorphisms with 
the susceptibility of RA in Saudi patients.
Patients and methods: This case control study consisted of 232 Saudi subjects including 106 RA patients and 126 matched controls. 
Genomic DNA was extracted using QIAampR DNA mini kit (Qiagen CA, USA). TNF-α and TNF-β genes were amplified using Arms 
primers.
Results: The frequencies of TNF-α (−308) allele G and genotype GG were significantly higher in RA patients as compared to   controls 
while allele A and genotype AA were predominant in control group. On the other hand the frequency of TNF-β (+252) GG and   AA 
  genotypes were significantly higher in RA patients as compared to controls while GA genotype was predominant in controls. It was 
inferred that genotype GG positive individuals at position −308 of TNF-α were susceptible to RA while genotype AA might has a 
protective effect on RA susceptibility in Saudis. Whereas GG and AA genotype of TNF-β at +252 position might exert additive sus-
ceptibility to RA and GA might be refractory. However, there was no significant association between duration of morning stiffness, RF 
positivity and number of joints involved and distribution of alleles/genotypes of TNF-α (−308) or TNF-β (+252) polymorphism. It may 
be concluded that the TNF-α (−308) and TNF-β (+252) polymorphisms might influence the susceptibility to RA in Saudi population. 
These results might have prognostic value for future clinical observations.
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Introduction
Rheumatoid arthritis (RA) is a chronic inflammatory auto-
immune disease affecting 0.5 to 2% of the world’s popula-
tion. Abundant expression of pro- and   anti-inflammatory 
cytokines observed in the affected tissues and serum of 
RA patients clearly indicates the involvement of cytok-
ines in the etiopathology of  RA.1 Tumor  necrosis factor 
(TNF), a pro-  inflammatory cytokine has been shown to 
play a pivotal role in the pathogenesis of several autoim-
mune diseases including RA.1–3 This is further evident 
from significantly high levels of TNF in the synovial 
fluid of RA patients.
TNF-α and TNF-β are closely related cytokines 
that  share  30%  amino  acid  residues  and  use  the-
same cell surface receptor.4 Nedwin et al5 reported 
that  the  TNF-α  and  TNF-β  genes  are  located  in 
tandem on chromosome 6 between the Class I and 
Class II cluster of the major histocompatibility com-
plex  (chromosome  6p21.1–6p21.3).  Among  the 
five polymorphisms (at position +691,−238, −308, 
−851, and −857) of TNFα gene identified by PCR-
SSCP analysis, TNFα −308 polymorphism has been 
reported to be associated with several autoimmune 
diseases including RA.6,7 The genetic variation on 
position −308 results in two allelic forms in which the 
presence of guanine (G) defines the common variant 
and the presence of adenine (A) defines the less com-
mon one. TNFα-308A-allele displays increased gene 
transcription as compared to the common allele G.8 It 
has been shown to produce 6–7 fold higher levels of 
TNF-α transcription.8,9 
Tumor necrosis factor β (TNF-β) which is closely 
linked to TNF-α, has also been shown to contribute to 
the susceptibility of several autoimmune diseases.10,11 
A polymorphism has been reported at position +252 
within the first intron of the TNF-β gene, consisting 
of a Guanine (TNF-β +252G) on one allele and an 
Adenine  (TNF-β  +252Α)  on  the  alternate  allele.12 
The presence of G at this position defines the mutant 
allele known as TNF-β ∗ 1 (allele-1) which is less 
frequent  allele  in  white  subjects  and  is  associated 
with  higher  TNF-α  and  TNF−β  production.12,13 
Recently a study on Japanese population has shown 
that TNFβ (+252) polymorphism together with HLA-
DRB1*0405   influences the susceptibility to RA.14
Overall  the  data  related  to  allele  and  genotype 
distribution of TNF-α and TNF-β polymorphisms in 
RA patients from various populations is limited and 
inconclusive. In this study an attempt was made to 
determine a possible association of TNF-α (G−308A) 
and  TNF-β  (A+252G)  polymorphism  with  RA  in 
Saudi population.
Materials and Methods
Patients and controls
A  total  of  232  subjects  visiting  Armed  Forces 
  Hospital, Riyadh, Saudi Arabia were recruited (during 
2007–2008) for this study. The diagnosis of RA was 
made according to the revised criteria of American Col-
lege of  Rheumatology.15 RA group consisted of 106 
unrelated Saudi RA patients [male = 21, female = 85, 
age range 26 to 75 years (mean age 49 ± 12.5 years)]. 
The control group consisted of 126 matched, unre-
lated healthy blood donors [male = 50, female = 76, 
age range 25 to 70 years (mean age 48 ± 11.5 years)] 
from the same Saudi population.
PCR amplification
Genomic DNA was extracted from the peripheral 
blood of RA patients and controls using QIAampR 
DNA mini kit (Qiagen CA, USA). TNF-α and TNF-β 
genes were amplified using amplification refractory 
mutation systems (ARMS)-PCR   methodology16 to 
detect any polymorphism involved at position −308 
of TNF-α and position +252 in Interon1 of TNF-β 
gene respectively. The set of primers used to amplify 
target DNA in the promoter region of TNF-α and 
TNF-β  genes  are  summarized  in  Table  1.  PCR 
amplification  was  carried  out  using  Ready  to  Go 
PCR Beads (Amersham Biosciences, USA). Reac-
tion consisted of 10 temperature cycles of denatur-
ation for 15 s at 94 °C, annealing for 50 s at 65 °C 
and extension for 40 s at 72 °C. Then 25 cycles of 
denaturation for 20 s at 94 °C, annealing for 50 s at 
59 °C and extension for 50 s at 72 °C. Final exten-
sion was performed at 72 °C for 7 min. A positive 
control was included in the PCR assay by amplifica-
tion of the human growth hormone (HGH) gene. The 
amplified product for various samples were sepa-
rated on the 1.5% agarose gel, stained with ethidium 
bromide and photographed.
Statistical analysis
The  differences  in  allele/genotype  frequencies 
between  patients  and  controls  were  analyzed  by 
the Fisher’s exact test. P values less than 0.05 were TnF polymorphism and rheumatoid arthritis
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Results
The demographic and clinical characteristics of the 
RA patients are summarized in Table 2. Based on 
clinical  history  the  mean  duration  of  disease  was 
found to be 9 ± 4.5 years. Number of joints involved 
varied from 2 to 22. Depending on the number joints 
involved RA patients were classified into two groups: 
polyarthritis patients (87.74%) with more than 5 joints 
involved and oligoarthritis (12.26%) with less than 
5 joints involved. Morning stiffness duration varied 
from 10 minutes in mildly affected to several hour 
in severely affected patients. Number of swollen and 
tender joints ranged from 0 to 22. Serological results 
indicated that 82 (77.36%) patients were rheumatoid 
factor (RF) positive while 24 (22.64%) RF negative.
The genotypes and alleles frequencies of TNF-α 
−308  promoter  polymorphism  in  RA  patients  and 
control  individuals  are  presented  in  Table  3.  The 
frequency of allele-A was significantly lower in RA 
patients as compared to control group (P = 0.005, 
RR = 0.48, PF = 0.242) on the other hand the frequency 
Table 1. Showing sets of sense and antisense primers used to amplify the TnF-α and TnF-β to detect polymorphism.
Locus Generic (antisense) primer sense primers
TnFα (g-308A) 5′-TCT Cgg TTT CTT CTC CAT Cg-3′ 5′-ATA ggT TTT gAg ggg CAT gg-3′ 
5′-AAT Agg TTT TgA ggg gCA TgA-3′
TnFβ (interon1 + 252) 5′-AgA TCg ACA gAg AAg ggg ACA 3′ 5′-CAT TCT CTg TTT CTg CCA Tgg-3′ 
5′-CAT TCT CTg TTT CTg CCA TgA-3′
  considered significant. The strength of the association 
of disease with respect to a particular allele/genotype 
is expressed by odd ratio interpreted as relative risk 
(RR) following the Woolf’s method as out lined by 
Schallreuter et al.17 It was calculated only for those 
alleles/genotypes which were increased or decreased 
in arthritis patients as compared to control group. The 
RR was calculated for all the subjects using the for-
mula given below:
  RR = (a) × (d)/(b) × (c)
a =   number of patients with expression of allele or 
genotype
b =   number of patients without expression of allele 
or genotype
c =   number of controls with expression of allele or 
genotype
d =   number of controls without expression of allele 
or genotype.
etiologic Fraction (eF)
The EF indicates the hypothetical genetic component of 
the disease. The values .0.0–0.99 are of   significance. 
EF was calculated for positive association only where 
RR . 1 using the following formula.18
  EF = (RR-1)f/RR, where f = a/a+c
Preventive Fraction (PF)
The PF indicates the hypothetical protective effect 
of  one  specific  allele/genotype  for  the  disease.  PF 
was calculated for negative association only where 
RR , 1 using the following formula.18
PF = (1-RR)f/RR (1-f) + f, where f = a/a+c
Values ,1.0 indicate the protective effect of the allele/
genotype against the manifestation of disease.
Table  2.  Demographic  and  clinical  characteristics  of 
rA patients.
no. of patients 106 (F = 85, M = 21)
Age 49 ± 12.5 (26–75 years)
Age of onset 40 ± 10.5 (20–69 years)
Disease duration 9 ± 4.5 (2–34 years)
no. of joints involved 10 (2–22)
Polyarthritis  
(.5 joints involved)
93
Oligoarthritis  
(,5 joints involved)
13
Swollen joints count 6 (0–22)
Tender joints count 5 (0–22)
rF positive 82
rF negative 24
rF 210 IU/ml (85–760 IU/ml)
eSr 28 (2–127 mm/h)
C-reactive protein 20 (3–155 mg/l)
note: Parameters are presented as mean ± standard deviation (range) 
or number.Al-rayes et al
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of allele-G was higher in RA patients as compared to 
the controls (P = 0.005, RR = 1.87, and EF = 0.242). 
The homozygous GG genotype was present in 64.15% 
of the RA patients and 50% of controls (P = 0.033), 
while heterozygous GA was found in 33.01% of RA 
patients against 38.09% of controls (P = 0.492). The 
homozygous AA genotype was found in 2.83% of RA 
patients and 11.90% of control samples (P = 0.012). 
Allele-A containing genotypes (GA and AA) were 
present in 35.84% of patients and 50% of the healthy 
controls (P = 0.033). Susceptibility to RA was signifi-
cant for homozygote for TNF-α 308 G-allele (GG) 
(P = 0.033; RR = 1.789; EP = 0.261). The predomi-
nance of GG genotype among the patients group indi-
cated that the GG genotype was associated with the 
susceptibility to RA while AA has protective effect 
on the susceptibility to RA as it was more common in 
control samples (P = 0.012, RR = 0.25, PF = 0.337). 
G-Allele (1-allele) of TNF-α seems to be susceptible 
to RA (P = 0.005, RR = 1.87, and EF = 0.242) whereas 
A-Allele (2-allele) of TNF-α seems to be resistant to 
RA in Saudis (P = 0.005, RR = 0.48, PF = 0.242).
The  distribution  of  genotypes  and  alleles  fre-
quencies of TNF-α −308 promoter polymorphism 
in  relation  to  duration  of  morning  stiffness,  RF 
positive or RF negative and type of arthritis (pol-
yarthritis  and  oligoarthritis)  is  given  in  Table  4. 
There was no significant association between dura-
tion of morning stiffness, RF positivity and number 
of joints involved (polyarthritis/oligoarthritis) and 
distribution  of  alleles/genotypes  of  TNF-α  −308 
polymorphism.
The distributions of genotype and allele frequen-
cies  of  TNF-β ( +252)  promoter  polymorphism  in 
Saudi  patients  with  RA  and  controls  subjects  are 
  summarized in Table 5. The frequency of GG, GA and 
AA genotypes of TNF−β (+252) showed statistically 
significant differences between patients and controls. 
The GG and AA genotypes were significantly over-
represented in RA patients as compared to the con-
trols (P = 0.044 and P = 0.0009 respectively) while 
GA genotype was significantly higher in controls as 
compared to RA patients (P = 0.0001). These results 
indicated that GG and AA genotypes at +252 were 
susceptible  to  RA  (RR  =  2.050,  EF  =  0.254,  and 
RR = 3.523. EF = 0.472 respectively), on the other 
hand GA was found to be refractory (RR = 0.282, 
PF = 0.441). Though there were differences in the fre-
quency distribution of allele-A and allele-G of TNF-β 
(+252) polymorphisms in Saudi RA patients and con-
trols however these differences were not statistically 
significant (P = 0.457).
The  distribution  of  genotypes  and  alleles  fre-
quencies of TNF-β (+252) polymorphism in rela-
tion to duration of morning stiffness, RF positive 
or  RF  negative  and  polyarthritis/oligoarthritis  is 
given in Table 6. Analysis of data suggested that 
there was no significant association between dura-
tion of morning stiffness, RF positivity and num-
ber of joints involved (polyarthritis/oligoarthritis) 
and alleles/genotypes frequency of TNF-β (+252) 
polymorphism.
The  comparison  between  the  frequencies  of 
genotypes  of  TNF-α  (G−308Α)  promoter  poly-
morphism  in  Saudi  healthy  population  with  the 
frequencies reported for healthy population of vari-
ous ethnicities worldwide is presented in Table 7. 
These results clearly indicated ethnic variations in 
genotype distribution of TNF-α (−308)  promoter 
polymorphism.
Table 3. genotype and allele frequencies of TnFα (g-308A) polymorphism in rA patients and matched controls.
Genotype/allele RA  
(n = 106)
control  
(n = 126)
P-value RR eF*/pF
n % n %
gg 68 64.15 63 50 0.033♣ 1.79 0.261*
gA 35 33.01 48 38.09 0.492 0.66 0.156
AA 3 2.83 15 11.90 0.012♣ 0.25 0.337
gA and AA 38 35.84 63 50 0.033♣ 0.55 0.223
g-allele 171 80.66 174 69.04 0.005♣ 1.87 0.242*
A-allele 41 19.33 78 30.95 0.005♣ 0.48 0.242
note: n, number of subjects; ♣Statistically significant. 
Abbreviations: eF, etiological fraction; PF, preventive fraction.TnF polymorphism and rheumatoid arthritis
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Discussion
This is the first study dealing with the TNF-α and 
TNF-β polymorphism in Saudi population with RA. 
Our  results  showing  significantly  lower  frequency 
of −308A allele and higher frequency of −308G allele 
in RA patients as compared to healthy controls are 
similar to the findings reported in various other eth-
nic  groups  including  Taiwan  Chinese,19  Japanese,20 
Swedish,21 Turkish,22 Hungarian23 and Han population 
of Eastern China.7 This study along with other pub-
lished reports supported the view that −308 Α allele of 
TNF-α may exert a protective influence for the devel-
opment of RA. Contrary to our findings the reports 
from Australian Caucasian,24 Spanish,25 Mexicans,26 
  American Caucasians6 and Chilean27 showed signifi-
cantly higher frequency of Allele-A in RA patients as 
compared to control group. On the other hand no sig-
nificant difference in frequency of Allele-A in controls 
and RA patient was observed in Taiwanese,28 Polish,29 
  Iranian30  and  Turkish  populations.31  Nemec  et  al32 
found no significant difference in genotype and allelic 
frequencies of TNF-α (−308) polymorphism in Czech 
population with and without RA.
The  exact  reason  for  such  a  vast  variation  in 
the distribution of alleles and genotypes of TNF-α 
(−308) polymorphism in RA patients in different eth-
nic groups is far from clear. These differences may 
be attributed to the ethnicity related genetic makeup 
in  different  populations  which  is  evident  from  the 
genotype data of TNF-α (−308) polymorphism pub-
lished from various ethnic healthy groups worldwide 
(Table 7). Lee et al33 also suggested that ethnicity has 
a significant impact on the genotype distribution of 
TNF-α (−308) polymorphism in RA patients. RA is 
considered to be a complex disorder and its onset and 
severity is influenced by genetic as well as environ-
mental factors. Hence the gene-environment interac-
tion are likely to play a significant role on the outcome 
of polymorphism association studies on RA patients.
In this study no significant association was found 
between the TNF-α (−308) polymorphism and clini-
cal features of RA such as number of joints involved, 
RF  positivity  and  duration  of  morning  stiffness. 
  Similar to our results Ates et al.34 also reported no 
association between TNF-α (−308) polymorphism 
and RF positivity and erosive disease of RA in   Turkish 
patients. However, the association of the alleles and 
genotypes  of  TNF-α ( −308)  polymorphism  has Al-rayes et al
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Table 5. genotype and allele frequencies of TnFβ (g+252A) polymorphism in rA patients and matched controls.
Genotype/allele RA  
(n = 106)
control  
(n = 126)
P-value RR eF*/pF
n % n %
gg 27 25.47 18 14.28 0.044♣ 2.050 0.254*
gA 47 44.33 93 73.80 0.0001♣ 0.282 0.441
AA 32 30.18 15 11.90 0.0009♣ 3.523 0.472*
gA and AA 79 74.52 108 85.71 0.044♣ 0.487 0.288
g-allele 101 47.64 129 51.19 0.457 0.954 0.089
A-allele 111 52.35 123 48.80 0.457 1.152 0.088*
note: n, number of subjects; ♣Statistically significant.
Abbreviations: eF, etiological fraction; PF, preventive fraction.
been  reported  with  severity  of  RA  in  American, 
Mexican and Czech populations.6,26,32 Khanna et al6 
found an association between TNF-α (−308) poly-
morphism  and  progression  of  radiographic  dam-
age  in  American  patients  with  early  seropositive 
RA,  and  suggested  that  the  association  might  be 
dependent on genetic variants in linkage disequilib-
rium with TNF-α (−308) A-allele and DRB1*0301. 
Rodriguiz-Carreon et al26 also found an association 
between TNF-α (−308) A-allele and severity of RA 
in   Mexicans but independent of HLA-DR alleles. On 
the other hand Nemec et al32 found no difference in 
the distribution of genotypes and alleles frequencies 
between the Czech RA patients and control group. 
However, on dividing the RA group according to the 
radio graphical progression of disease they (loc.cit) 
noticed significant difference in the distribution of 
genotypes and suggested that GG genotype of TNF-a 
(−308) polymorphism is associated with the severity 
of RA in Czech.32
Our  results  for  TNF-β ( +252)  promoter  poly-
morphism  indicted  that  GG  and  AA  genotype 
were susceptible to RA while GA was refractory. 
Recently  Panoulas10 also  reported  that  GG  geno-
type of TNF-β (+252) polymorphism occurs more 
frequently  in  RA  patients  as  compared  to  gen-
eral population. Earlier study from our laboratory 
showed an association of HLA-DRB1*04 and RA 
in Saudi patients.35 Thus it may be postulated that 
GG  and  AA  genotypes  of  TNF-β  together  with 
HLA-DRB1*04 might contribute to the RA suscep-
tibility in Saudi population. Association of TNF-β 
alleles  and  HLA  alleles  with  RA  has  also  been 
reported in Japanese population.14 These investiga-
tors reported that TNF-β * 2 (allele-A) along with 
  HLA-DRB1*0405 contributed to the susceptibility to 
RA. Genetic variations in the TNF and HLA-DRB1 
region have also been reported to affect the response 
to treatment of early RA.36 In our study there was no 
significant association between the number of joints 
involved, RF positivity, duration of morning stiff-
ness in Saudi RA patients and TNF-β (+252) poly-
morphism similar to TNF-α (−308) polymorphism.
Association  of  TNF-β  polymorphism  has  also 
been reported with various other autoimmune disor-
ders including Graves’ disease,37 idiopathic membra-
nous  glomerulonephritis,  IgA  nephropathy,  insulin 
dependent  diabetes  mellitus,38 myasthenia  gravis,39 
asthma  diathesis,40  SLE  with  nephritis,41  systemic 
sclerosis42  and  plaque  psoriasis.43  This  study  indi-
cates that besides its role in numerous autoimmune 
diseases TNF-β polymorphism is also involved in the 
pathogenesis of RA.
The present study suggested a significant asso-
ciation  between  allele  frequency  and  genotype 
distribution  of  TNF-α ( −308)  and  TNF-β ( +252) 
polymorphisms  and  RA  susceptibility  in  Saudi 
  population. Our results together with other published 
reports supported an important role of ethnicity in 
the association of TNF-α and TNF-β polymorphism 
and RA. It is also concluded that TNF-α (−308) and 
TNF-β (+252) polymorphisms may work in tandem 
in the pathogenesis of RA in Saudi population. The 
results of this study may have prognostic value for 
future clinical observations of RA patients. Further, 
TNFα (−308) polymorphism may provide guideline 
in determining the response to anti-TNF α therapy 
as patients with GG genotype are better respond-
ers  to  anti-TNFα  treatment  than  those  with  AA 
or GA.44–46TnF polymorphism and rheumatoid arthritis
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Table 7. genotype distribution of TnF-α (−308) promoter 
polymorphism in different healthy groups.
population/ 
group  
studied
Genotype  
frequencies (%)
Reference
GG GA AA
Saudis 50.0 38.09 11.90 Present study
American 68.2 29.1 2.7 47
Australian 58.0 39.0 3.0 48
Chilean 83.1 16.3 0.6 49
Chinese 85.6 13.3 1.1 7
Chinese 83.2 15.7 1.1 50
Czech 80.66 19.33 0.0 32
Danish 65.8 30.5 3.7 51
Dutch 56.6 38.6 4.5 52
english 59.6 37.4 3.0 53
Finish 68.8 30.0 1.3 54
French 81.6 17.2 1.2 55
german 67.0 28.0 5.0 56
Iranian 96.7 3.3 0.0 30
Japanese 97.0 3.0 0.0 57
Mexican 91.4 8.6 0.0 26
Spanish 82.4 15.7 1.9 25
Swedish 56.5 40.5 3.0 58
Taiwanese 83.4 15.8 0.8 28
West African 81.6 17.0 1.4 59
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